Smartleaf Asset Management LLC Purchases 216 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Smartleaf Asset Management LLC lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 95.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 442 shares of the biotechnology company’s stock after buying an additional 216 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Sarepta Therapeutics were worth $54,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Simplify Asset Management Inc. grew its stake in shares of Sarepta Therapeutics by 84.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after buying an additional 88,474 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares during the last quarter. Summit Partners Public Asset Management LLC lifted its holdings in Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after purchasing an additional 116,800 shares during the last quarter. Larson Financial Group LLC lifted its holdings in Sarepta Therapeutics by 1,649.8% in the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 8,249 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Sarepta Therapeutics by 30.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 78,244 shares of the biotechnology company’s stock worth $9,772,000 after purchasing an additional 18,095 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $99.69 on Tuesday. The business’s fifty day moving average price is $113.68 and its two-hundred day moving average price is $120.98. Sarepta Therapeutics, Inc. has a fifty-two week low of $98.82 and a fifty-two week high of $173.25. The stock has a market capitalization of $9.67 billion, a price-to-earnings ratio of 79.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SRPT. Deutsche Bank Aktiengesellschaft began coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 target price for the company. HC Wainwright reiterated a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 27th. StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Scotiabank started coverage on Sarepta Therapeutics in a report on Friday. They set a “sector perform” rating and a $105.00 price target for the company. Finally, Piper Sandler cut their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $170.41.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.